# US 2021/0340502 A1 · Generation of Post-Mitotic Migratory Cortical Interneurons

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340502 A1
- Document ID: US20210340502A1
- Status: Published application
- Kind: A1
- Application number: 17/280,225
- Filed: 2019-09-26
- Published: 2021-11-04
- Earliest claimed: 2018-09-28
- Applicants: The McLean Hospital Corporation; New York Medical College
- Inventors: Sangmi Chung
- Web page: https://patentgrep.com/patent/US20210340502A1

## CPC

- C12N 5/0619: {Neurons}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- B01F 27/90: with paddles or arms
- C12N 2500/34: Sugars
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/405: Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/70: Enzymes
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2513/00: 3D culture
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01F: MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING (mixing paints B44D3/06)

## Abstract

The present disclosure provides populations of synchronized post-mitotic migratory cortical interneurons (cINS) derived from pluripotent stem cells and cell culture methods for generating said populations of cINs. The disclosure also provides efficient methods for cryopreservation of the derived cINs.

## Claims

### Claim 1

A method of generating MGE progenitors from pluripotent stem cells said method comprising the step of establishing sphere cultures from pluripotent stem cells under spinner culture conditions.

### Claim 2

A method of generating a synchronized culture of cINs, derived from pluripotent stem cells, comprising the step of culturing of said cells in the presence of one or more of the following components: CultureOne, gamma secretase inhibitor DAPT and CDK4/6 inhibitor PD0332991.

### Claim 3 (depends on 2)

The method of claim 2, wherein the concentration of Culture One is in the range of 1% -10%.

### Claim 4 (depends on 2)

The method of claim 2, wherein the concentration of DAPT is in a range of about 3-10 μM.

### Claim 5 (depends on 2)

The method of claim 2, wherein the concentration of PD0332991 is in the range of about 1-8 μM.

### Claim 6 (depends on 2)

The method of claim 2, wherein the components of CDP are 1% CultureOne, 10 μM DAPT and 2 μM PD0332991

### Claim 7 (depends on 2)

The method of claim 2, wherein the step of culturing is done in the presence of Trehalose.

### Claim 8 (depends on 7)

The method of claim 7, wherein the concentration of Trehalose is between about 0.1-0.4M.

### Claim 9 (depends on 8)

The method of claim 8, wherein the concentration of Trehalose is about 0.1 M.

### Claim 10

A method of cryopreserving synchronized cultures of cINs wherein said interneurons are cryopreserved in the presence of Trehalose.

### Claim 11 (depends on 2)

A population of synchronized cINs derived using the method of claim 2.

### Claim 12 (depends on 11)

A method of treating a host in need of said treatment comprising transplantation of the population of synchronized cINs of claim 11 into the host.

### Claim 13 (depends on 12)

The method of claim 12, wherein the host is in need of treatment of a neurological disorder.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cINS are autologous cells.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cINs are allogenic.

### Claim 16 (depends on 2)

The method of claim 2, wherein said cINs are characterized by the expression of one or more of the following markers, SOX6+, GAD+, B-tubulin+, NKX2.1, SST and MEF2C.
